Recently Viewed
Clear All
Subscribe to our newsletter
or
Today’s Range
52 Week Range
Liquidity
Market cap
$276 Mln
Revenue (TTM)
$32 Mln
Net Profit (TTM)
$0 Mln
ROE
-2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
190.1
Industry P/E
59.46
EV/EBITDA
-10.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$0
EPS
$-0.3
Face value
--
Shares outstanding
91,067,464
CFO
$-54.03 Mln
EBITDA
$-93.95 Mln
Net Profit
$-82.60 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Stereotaxis (STXS)
| 31.1 | 7.2 | 25.1 | 54.1 | 21.4 | -3.6 | 10.5 |
|
BSE Sensex
| 7.3 | 1.9 | 1.6 | 3.0 | 13.2 | 16.0 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Stereotaxis (STXS)
| 30.0 | -15.5 | -66.6 | 21.8 | -3.8 | 389.4 | 34.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Stereotaxis (STXS)
|
3.0 | 275.9 | 31.8 | -23.4 | -75.5 | -256.9 | -- | 190.1 |
| 130.5 | 9,309.4 | 3,964.8 | 437.6 | 16.1 | 11.3 | 21.7 | 2.4 | |
| 14.8 | 10,076.1 | 6,665.8 | 687.4 | 15.1 | 11.2 | 14.5 | 1.5 | |
| 23.1 | 11,859.5 | 10,887.0 | -155.0 | 0.3 | -2.3 | -- | 1.6 | |
| 310.0 | 8,251.5 | 2,554.2 | 319.2 | 19.5 | 4.7 | 28 | 1.1 | |
| 63.0 | 7,670.2 | 12,773.0 | 389.0 | 5.2 | 11 | 20.3 | 2.3 | |
| 95.5 | 14,294.1 | 4,284.0 | 1,258.0 | 35.2 | 50.5 | 11.8 | 6.8 | |
| 146.8 | 8,070.5 | 1,848.2 | -459.2 | -10.2 | -43.8 | -- | 7.6 | |
| 249.0 | 9,710.8 | 1,280.2 | 147.7 | 13.6 | 12.1 | 65.9 | 7.6 | |
| 152.6 | 8,411.6 | 674.0 | -13.8 | 8.5 | -0.7 | -- | 4.0 |
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such... as the Genesis RMN, which enable physicians to complete interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN, which is designed to enhance the accessibility of RMN by eliminating the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; V-CAS; and MAGiC catheter for cardiac ablation procedures. Further, it provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri. Read more
CEO & Chairman
Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
CEO & Chairman
Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
Headquarters
Saint Louis, MO
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Stereotaxis Inc (STXS) is $2.99 (NYSE) as of 17-Oct-2025 16:00 EDT. Stereotaxis Inc (STXS) has given a return of 21.43% in the last 3 years.
Since, TTM earnings of Stereotaxis Inc (STXS) is negative, P/E ratio is not available.
The P/B ratio of Stereotaxis Inc (STXS) is 190.14 times as on 17-Oct-2025, a 5697 premium to its peers’ median range of 3.28 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-8.23
|
17.32
|
|
2023
|
-6.99
|
8.86
|
|
2022
|
-8.25
|
4.95
|
|
2021
|
-43.86
|
11.92
|
|
2020
|
-59.12
|
9.48
|
The 52-week high and low of Stereotaxis Inc (STXS) are Rs 3.59 and Rs 1.54 as of 19-Oct-2025.
Stereotaxis Inc (STXS) has a market capitalisation of $ 276 Mln as on 17-Oct-2025. As per Value Research classification, it is a Small Cap company.
Before investing in Stereotaxis Inc (STXS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.04
(
